FPR1 and triple-negative breast carcinoma: FPR1, a G protein-coupled receptor, has been implicated in both innate and adaptive immunity.[44,45] Vecchi et al[46] conducted a study demonstrating the inhibitory effects of FPR1 inhibitors on the growth and metastasis of triple-negative breast cancer.